Menu
ETF
Annual · values202520242023
Operating Cash Flow-38.21 M CAD-23.45 M CAD-22.61 M CAD
Depreciation & Amortization373000 CAD707000 CAD727000 CAD
Stock-Based Compensation5.49 M CAD2.58 M CAD3.42 M CAD
Capital Expenditures176000 CAD
Cash Flow from Investing-242000 CAD
Cash Flow from Financing41.14 M CAD54.70 M CAD1.76 M CAD
Dividends Paid
Stock Buybacks
Free Cash Flow-38.38 M CAD

Profound Medical Corp. is a pioneering company in the medical technology sector, specializing in the development of innovative therapeutic platforms for treating prostate issues, breast cancer, and uterine fibroids. The core function of Profound Medical Corp. is to provide minimally invasive therapeutic solutions, leveraging its proprietary technologies to improve patient outcomes and enhance the efficacy of treatments. The company's proprietary TULSA-PRO and SONALLEVE systems integrate ultrasound imaging with precise ablation capabilities, offering non-invasive options for patients. These technologies are particularly significant in the healthcare sector as they aim to reduce recovery time, lower the risk of complications, and improve overall treatment experiences. By focusing on areas such as oncology and men’s health, Profound Medical Corp. plays a crucial role in advancing medical treatments and improving the quality of life for patients. The company's innovations are poised to impact hospitals, clinics, and specialized medical facilities globally, marking a significant advancement in non-surgical therapeutic strategies."